Hermed Capital Co. Team

PH.D in Immunopharmacology, Postdoctoral Fellow at Rochester University. Received grant from NIH/NCI Faculty Development Program and "2005 Excellent Award" from Rochester University. Founded Hermed Capital in 2015, built and led the team completed the investment of Hermed Fund I since then. A board member of Chongqing Fochon, Henlius (02696, HK), Beyond Spring Pharma (BYSI,NASD), Diamedica (DMAC, NASD). Aadi Bioscience and Applied Stemcell. He was Deputy head of Fosun Pharma's H-share IPO team, advisor of Bio China and the member of the Investment subcommittee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA). Prior to Hermed Capital, Jerry was the Vice President of Research Institute of Fosun Pharmaceutical (Group) Co., Ltd, responsible for BD and VC business of the group, successfully built the small molecule and large molecule platform for Fosun Pharma, and was responsible for the management and project licensing of R&D. He led the establishment of Henlius (02696, HK) in December 2009, helping the team grow from a start-up to a unicorn, with more than 100 times return in 9 years. In 2012, he invested in Beyond Spring Pharma in angel round, which has become Fosun Pharma's first NASDAQ-listed biopharmaceutical company (BYSI, NASDAQ, IPO in 2017). The company licensed out patent to Eli Lilly in 2020, with a total contract value of $790 million.